across both human and animal health market segments.
The new site will increase Syngene’s total single-use bioreactor capacity to 50,000L for large molecule discovery, development, and manufacturing services.Also Read: Syngene International Q3 Results | Net profit rises 18% to ₹131 crore, revenue up 11% to ₹944 crore
Additionally, it will provide Syngene’s customers with continuity of supply from its four development and manufacturing facilities located in India and North America, offering services ranging from cell line development, process optimisation and both clinical and commercial supply.
Syngene’s investment in its first facility in the United States marks a strategic commitment to the US market, with significant benefits for the local economy and the broader life sciences industry.The facility is expected to create jobs, stimulate local economic activity, and strengthen domestic biologics manufacturing capabilities while also contributing to pharmaceutical innovation and supply chain resilience.
Also Read: Biocon confirms sale of 80 lakh Syngene Intl shares for ₹686 crore via open market block deal
Peter Bains, CEO Designate, Syngene International said, “With one of the largest biologics R&D teams and commercial scale manufacturing capabilities in both India and the USA, we now offer a compelling and flexible solution for global pharma and biotech customers.
This investment will enable Syngene to cater to growing client requirements in an expanding market. It will also provide clients access to collective service capability of multiple geographic sites, scientists and experience.”
Shares of Syngene International Ltd ended at ₹677.15, down by ₹2.35, or 0.35%, on the BSE.
Also Read: Biocon Biologics’ biosimilar Yesintek shows positive phase 3 results for psoriasis treatment
